Final Days to Register!

The biomedical industry is under enormous pressure to produce faster results, while also finding ways to reduce costs. Examples abound in one industry after another of how researchers have gained tremendous advantages by collaborating on pre-competitive efforts, but such efforts have been limited in biomedical research, where researchers often find it difficult to openly share data within their own organization, much less with competitors. Working together, sharing information, and data sets and costs, all have significant potential for improved performance, but only when such efforts make use of best practices and lessons learned from existing projects.

Cambridge Healthtech Institute’s Collaborative Innovation in Biomedicine aims to bring together a number of experts with practical experience in organizing, managing, funding, and getting results from such projects. While there are real challenges with shared resources, IP protection, differing goals, and finding ways to equalize value contributions and benefits gains, some of the biggest challenges are based on firmly held beliefs about the risks of working together and narrow conceptions of what really constitute pre-competitive space. A key goal of the program is to provide attendees with a number of key strategies for identifying when and how collaborative innovation can and should be encouraged, as well as when such efforts are less likely to produce useful results.

Distinguished Faculty:

Bryn Williams-Jones, Ph.D., Associate Research Fellow; Head, eBiology, Pfizer
Darrell Abernethy, Ph.D., Associate Director, Drug Safety, Office of Clinical Pharmacology, Food and Drug Administration
David Cook, Ph.D., Global Safety Assessment, AstraZeneca Pharmaceuticals
Eric Thompson, Ph.D., Assistant Director, Predictive Safety Testing Consortium, Critical Path Institute
Jackie Hunter, Ph.D., Senior Vice President, Science Environment Development, GlaxoSmithKline
Jean-Robert Ioset, Professor, Project Coordinator, Research & Development, Drugs for Neglected Diseases initiative (DNDi)
John Overington, Ph.D., Team Leader, Chemogenomics, EMBL-EBI, Wellcome Trust Genome Campus
Les Jordan, Chief Technology Strategist, Microsoft Life Sciences
Mariana Guergova-Kuras, Ph.D., Director of Research, Biosystems International
Max Fehlmann, Ph.D., President & CEO, Quebec Consortium of Drug Discovery
Ramesh Durvasula, Ph.D., Director, Chemistry Informatics, Research Informatics & Automation, Bristol-Myers Squibb
Robert Porter-Lynch, Ph.D., CEO, The Warren Group; Managing Partner, System of Trust, LLC
Robin Spencer, Ph.D., Senior Fellow, Research Centers of Emphasis, Pfizer, Inc.
Sandor Szalma, Ph.D., Senior Research Fellow, Research & Development Informatics, Centocor R&D, Inc.
Sean Ekins, Ph.D., Collaborations Director, Research & Development, Collaborative Drug Discovery
Shawnmarie Mayrand-Chung, Ph.D., NIH Director for The Biomarkers Consortium & Senior Advisor to The Biomarkers Consortium
Stefan J. Platz, Ph.D., Head, Toxicology & Pathology, F. Hoffman-LaRoche Ltd.
Syril D. Pettit, Ph.D., MEM, Associate Director, HESI, ILSI
Veronique Kiermer, Ph.D., Publisher, Nature Methods, Protocols, and Products, Nature Publishing Group

Agenda: Day 1 | Day 2 | Day 3 

For more details on the conference, please contact:
Phillips Kuhl
President
Cambridge Healthtech Institute
T: (+1) 781-972-5410
E: pkuhl@healthtech.com

For partnering and sponsorship information, please contact:
Arnie Wolfson
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5431
E: awolfson@healthtech.com